NCT07038551View on ClinicalTrials.gov

Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 6, 2025

Primary Completion Date

March 11, 2026

Study Completion Date

September 30, 2027

Conditions
Opioid-Induced Constipation (OIC)
Interventions
DRUG

Naldemedine

over-encapsulated capsule of either 0.2 mg of naldemedine

DRUG

Placebo

over-encapsulated capsule of placebo

Trial Locations (1)

Unknown

RECRUITING

International university of health and welfare Narita hospital, Narita

Sponsors

Collaborators (1)

Shionogi
All Listed Sponsors
collaborator

Shionogi

INDUSTRY

lead

International University of Health and Welfare

OTHER

NCT07038551 - Prophylactic Use of Naldemedine on Opioid-induced Nausea and Vomiting in Patients With Cancer: POSEIDON Study | Biotech Hunter | Biotech Hunter